leisure time -WSS

leisure time

author：hotspot 2025-09-02 08:08:46 - browse：2

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — A newly approved Alzheimer’s drug made by Eisai and Biogen, called Leqembi, aims to clear out amyloid plaques in patients’ brains. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

WASHINGTON — Medicare on Monday proposed ending restrictions on how many PET scans patients can receive to detect amyloid plaques in their brains, which will offer physicians more options as they treat patients with a new drug to slow the progression of dementia.

The agency that oversees Medicare had previously restricted coverage to a single scan for patients who participated in clinical studies. Advocates had warned that could cause issues related to a new class of Alzheimer’s drugs designed to clear those plaques.

“We know there is significant interest in the medical community about new treatments that may be effective in slowing the development of Alzheimer’s disease. PET scans are an important part of diagnosis and treatment of Alzheimer’s disease,” Centers for Medicare and Medicaid Administrator Chiquita Brooks-LaSure said in a written statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Research misconduct: Proposed new rules face resistance

WSS

EU regulator recommends expanding Mounjaro approval to obesity

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Parkinson’s finding may lead to tests and, someday, treatments

Independent physicians launch a new lobbying group

Traditional Chinese medicine benefits explored in new JAMA study

Chimpanzees, like humans and whales, get menopause: Study

Wikipedia

leisure time

Wikipedia

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Cassava reveals details — and problems — with Alzheimer's study

BioMarin wins approval for gene therapy to treat hemophilia A

Maker of FluMist seeks to allow at

Duchenne breakthrough therapy leaves behind pioneering families

Telehealth options flood the market as retailers push virtual care

Alkermes shareholders re

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

After affirmative action ruling, medical educators look to 'holistic review'

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Wikipedia

Francis Collins on trust in science and how Covid communications failed

FDA has safety concerns on CRISPR

Telehealth options flood the market as retailers push virtual care

Paying for Covid pills will soon shift to insurers

Emergency medicine has repudiated 'excited delirium.' Now what?

Prior authorization will have to move faster under new Biden rule

hotspot

leisure time

hotspot

leisure time